Janus Henderson Group PLC Acquires 107,903 Shares of Lumexa Imaging Holdings, Inc. $LMRI

Janus Henderson Group PLC boosted its stake in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) by 5.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,100,356 shares of the company’s stock after buying an additional 107,903 shares during the period. Janus Henderson Group PLC’s holdings in Lumexa Imaging were worth $18,063,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Monashee Investment Management LLC bought a new stake in Lumexa Imaging in the 4th quarter valued at approximately $2,775,000. Seven Grand Managers LLC acquired a new stake in Lumexa Imaging in the fourth quarter valued at $11,942,000. Element Capital Management LLC bought a new position in Lumexa Imaging during the fourth quarter worth about $1,616,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Lumexa Imaging during the 4th quarter worth approximately $27,750,000. Finally, Hunter Associates Investment Management LLC bought a new position in Lumexa Imaging during the first quarter worth $1,231,000.

Lumexa Imaging Stock Up 8.2%

Lumexa Imaging stock opened at $11.26 on Tuesday. Lumexa Imaging Holdings, Inc. has a 52-week low of $6.45 and a 52-week high of $19.45. The firm has a 50 day moving average price of $10.16 and a two-hundred day moving average price of $11.07. The firm has a market cap of $1.08 billion and a price-to-earnings ratio of -19.08. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.40 and a current ratio of 1.40.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on LMRI shares. Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. Finally, Barclays decreased their price target on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Activity at Lumexa Imaging

In other Lumexa Imaging news, Director Brett Brodnax bought 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the transaction, the director directly owned 62,027 shares in the company, valued at approximately $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is currently owned by insiders.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).